MedTrace Logo

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

NCT03018626 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2017-07-28

No results posted yet for this study

Summary

This is a randomized, open-label, multi-center, phase 3 study evaluating the efficacy of R-ACVBP and DA-EPOCH-R in patients with newly diagnosed non-germinal b-cell-like diffuse large B-cell lymphoma

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG

Rituximab

rituximab (375 mg/m2) given intravenously (IV) on day 0

DRUG

Etoposide

Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)

DRUG

Doxorubicin

Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)

DRUG

Vincristine

Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)

DRUG

Cyclophosphamide

Cyclophosphamide(750 mg/m2)/dayg IV on days 5

DRUG

Prednisone

prednisone (100 mg) given orally bid on days 1 through to 5.

DRUG

Doxorubicin

Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,

DRUG

Cyclophosphamide

Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,

DRUG

Vindesine

Vindesine (2 mg/m2) given on days 1 and 5

DRUG

Bleomycin

Bleomycin (10 mg) given IV on days 1 and 5

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Ru Feng, M.D. · Department of Hematology, Nanfang Hospital, Southern Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-27
Primary Completion
2020-01-31
Completion
2021-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03018626 on ClinicalTrials.gov